Dehydroepiandrosterone (DHEA) and its sulfated form DHEA-S are the most abundant circulating steroids in the human body, produced primarily by the zona reticularis of the adrenal cortex with additional synthesis in the gonads and brain. DHEA serves as the primary precursor for the sex steroid hormones — testosterone and estrogens — in peripheral tissues, and as a neuroactive steroid in the brain, directly modulating neural receptors independent of its conversion to sex hormones.
DHEA's endogenous levels follow a striking age-related trajectory: peaking between ages 20–30 and declining by approximately 80% by age 80. This dramatic age-related decline — more pronounced than any other adrenal hormone — motivated decades of research into DHEA as an anti-aging hormone, and established it as the most commercially successful anti-aging supplement in the United States, available over-the-counter in doses from 5 to 100 mg.
In the brain, DHEA and DHEA-S act as neurosteroids with multiple receptor interactions. DHEA-S, like pregnenolone sulfate, acts as a negative allosteric modulator of GABA-A receptors and a positive allosteric modulator of NMDA receptors — giving it a similar neurological profile to pregnenolone sulfate: alerting, pro-cognitive, and potentially anxiogenic at higher doses. DHEA also activates sigma-1 receptors, TRPV1 channels, and interacts with androgen and estrogen receptors (being converted to these hormones in peripheral tissues). Additionally, DHEA has direct anti-glucocorticoid properties — opposing some actions of cortisol at the receptor and genomic level — which underpins its reputation for anti-stress and adaptogenic effects.
Clinical evidence for DHEA supplementation is most robust in elderly populations with documented DHEA deficiency, adrenal insufficiency, and women with low libido. Evidence for cognitive enhancement in healthy young adults is weak. The compound is widely used in the "nootropic stack" community for its mild pro-cognitive and mood-enhancing effects, frequently combined with pregnenolone.
Safety at a Glance
- Starting Dose and Individual Variation
- For those interested in DHEA supplementation:
- Toxicity: General Safety at Low Doses At doses of 25–50 mg/day, DHEA is generally well-tolerated. As an endogenous steroid, its...
- Start with a low dose and wait for onset before redosing
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
Oral
Duration
Oral
Total: 12 hrs – 24 hrsPharmacology
Synthesis and the DHEA "Curve"
DHEA is synthesized from pregnenolone by CYP17A1 (17α-hydroxylase/17,20-lyase) in the adrenal zona reticularis. It is sulfated to DHEA-S by SULT2A1 (sulfotransferase) in the adrenal and liver. DHEA-S serves as a large circulating reservoir — its plasma levels are ~500-fold higher than DHEA and its longer half-life (7–10 hours vs. 1–3 hours for DHEA) provides stable circulating levels. Target tissues convert DHEA-S back to DHEA (and onward to testosterone and estrogens) via tissue-specific enzymes.
The adrenarche (around age 6–8) marks the onset of significant DHEA/DHEA-S production. Levels peak in the mid-20s to mid-30s, then decline ~2% per year thereafter — one of the most reliable biomarkers of physiological aging.
Neuroactive Steroid Mechanisms
GABA-A receptor modulation: DHEA-S acts as a negative allosteric modulator of GABA-A receptors at multiple subunit interfaces. This reduces the potency of GABA's inhibitory action, producing a net excitatory effect (similar in direction to pregnenolone sulfate, though generally less potent). This mechanism likely underlies DHEA-S's alerting and pro-cognitive effects, and also explains potential anxiogenic effects at high doses.
NMDA receptor potentiation: DHEA-S modestly potentiates NMDA receptor function, enhancing glutamatergic neurotransmission and synaptic plasticity. This is mechanistically aligned with memory-enhancing effects observed in animal studies.
Sigma-1 receptor: DHEA is a sigma-1 receptor agonist. Sigma-1 receptors are ER-mitochondria interface chaperones that regulate calcium signaling, reduce ER stress, and promote neuroplasticity and neuroprotection.
Anti-glucocorticoid actions: DHEA competitively inhibits glucocorticoid receptor (GR) binding at supraphysiological concentrations and counteracts some cortisol-mediated effects at the gene expression level. This is the basis for proposed "anti-stress" and immunomodulatory properties — DHEA tends to shift the cortisol/DHEA ratio, which has been proposed as a biomarker of stress resilience.
Sex Hormone Conversion
The most significant systemic action of DHEA supplementation in many tissues is its conversion to sex hormones:
- In peripheral tissues (adipose, skin, liver, muscle, prostate, breast): DHEA is converted by 17β-HSD and aromatase to testosterone and estradiol
- In men: The major effect is estrogenic (via aromatization), with modest androgenic contribution
- In postmenopausal women: DHEA becomes a primary source of both androgens and estrogens in target tissues after gonadal production ceases
This intracrine conversion — happening within target cells without release into circulation — explains why DHEA can have sex hormone effects without necessarily producing large changes in circulating testosterone or estradiol.
Pharmacokinetics
Oral DHEA is well absorbed and rapidly converted by first-pass metabolism in the liver. Peak plasma levels occur 1–2 hours post-dose. Half-life is 1–3 hours for DHEA, substantially longer for DHEA-S. Sublingual or transdermal DHEA has better bioavailability (bypasses first-pass) and is preferred for maintaining higher DHEA levels relative to DHEA-S.
Interactions
No documented interactions.
History
Isolation and Initial Obscurity
DHEA was first isolated from human urine by Adolph Butenandt and H. Dannenbaum in 1934 — the same year that estrone and androsterone were characterized. However, DHEA languished in relative scientific obscurity for decades compared to the sex hormones and cortisol, as its function was unclear. It was classified initially as an "adrenal androgen" and its quantitative dominance in the circulation (far exceeding cortisol, testosterone, and estradiol) went without satisfying explanation.
Discovery of the Age-Related Decline
The recognition that DHEA and DHEA-S decline dramatically with age — beginning in the 30s and reaching very low levels by old age — emerged from large epidemiological studies in the 1980s. Samuel Yen at UCSD and Norman Orentreich were among the first to systematically characterize this decline and link it to aging. The inverse correlation between DHEA-S levels and mortality in men (lower DHEA-S associated with higher cardiovascular disease risk) sparked interest in DHEA as an anti-aging molecule.
The Anti-Aging Era
William Regelson, an oncologist, became one of the most prominent advocates for DHEA as an anti-aging supplement through the 1980s and 1990s. His popular book "The Superhormone Promise" brought DHEA to broad public attention. Following the 1994 Dietary Supplement Health and Education Act (DSHEA) in the United States — which removed many steroid supplements from FDA oversight — DHEA became legally available over-the-counter, making the United States an outlier globally (DHEA is a prescription-only drug in most countries and prohibited in sports).
Adrenal Insufficiency and Clinical Evidence
The most clinically robust evidence for DHEA supplementation comes from patients with adrenal insufficiency (Addison's disease, hypopituitarism), in whom DHEA is markedly deficient. Placebo-controlled trials in this population show improvements in quality of life, mood, sexuality, and body composition. This established proof-of-concept for DHEA replacement, though translation to healthy aging populations has been less consistent.
Sports and Prohibition
DHEA has been banned by the World Anti-Doping Agency (WADA) since 1996 as a prohibited anabolic androgenic steroid precursor. This has not prevented its widespread OTC sale in the US, creating a situation where an substance prohibited in sport is freely available as a supplement.
Harm Reduction
Starting Dose and Individual Variation
For those interested in DHEA supplementation:
Start low: 5–25 mg/day is an appropriate starting range. The widely available 50 mg tablets are likely high for many users, particularly younger individuals. Doses above 25 mg may produce more pronounced androgenic effects.
Consider testing first: Salivary DHEA-S testing (available through online labs without a prescription in most US states) provides a baseline. If your DHEA-S is in the normal-for-your-age range, supplementation benefit may be minimal; if low, the case for supplementation is stronger.
Morning dosing: DHEA follows the natural cortisol/DHEA morning peak. Morning supplementation aligns with endogenous rhythm and avoids sleep disruption from alerting effects.
Sex-specific dosing: Women generally require lower doses than men to achieve equivalent effects; the threshold for androgenic side effects is reached at lower doses in women. Many practitioners recommend 5–10 mg for women vs. 25–50 mg for men when supplementing without documented deficiency.
DHEA and Psychoactive Drug Use
Cortisol balance: DHEA's anti-glucocorticoid properties may provide some protection against stress-related cortisol excess — relevant to users who experience HPA axis dysregulation from stimulant use or chronic stress. Some evidence suggests DHEA supplementation improves cortisol/DHEA ratio and reduces perceived stress.
Anti-aging stack context: DHEA is commonly combined with pregnenolone in nootropic stacks, where synergistic neurosteroid effects are sought. The combination of both can amplify both the pro-cognitive and androgenic effects; dose-monitoring is especially important in combination.
Contraindications
- Hormone-sensitive cancers (prostate, breast, ovarian, endometrial)
- Pregnancy and breastfeeding
- Polycystic ovarian syndrome (already elevated androgens)
- Active liver disease
- Under 30 without documented DHEA deficiency (natural levels typically adequate)
Toxicity & Safety
General Safety at Low Doses
At doses of 25–50 mg/day, DHEA is generally well-tolerated. As an endogenous steroid, its metabolic pathways are well-characterized. The primary safety concerns relate to androgenic/estrogenic effects from downstream conversion:
Androgenic effects: Acne, oily skin, facial hair growth (women), voice deepening (women), potential exacerbation of androgenic alopecia Estrogenic effects: Breast tenderness, potential contribution to estrogen-dependent conditions
These effects are dose-dependent and more significant at doses above 50 mg/day.
Cancer Risk Considerations
Hormone-sensitive cancers: DHEA should not be used without medical supervision in individuals with or at risk for hormone-sensitive cancers (prostate cancer, breast cancer, ovarian cancer, endometrial cancer). DHEA conversion to estradiol or testosterone could theoretically promote growth of hormone-sensitive tumors. This is a genuine concern that warrants caution, not dismissed risk.
Androgenic in Women
Women are more likely than men to experience androgenic side effects from DHEA supplementation because their baseline androgen levels are lower. Even modest DHEA supplementation can shift androgen levels significantly, producing acne, hirsutism, and menstrual irregularities.
Age Considerations
In younger adults with normal DHEA levels, supplementation may push DHEA-S above physiological ranges, amplifying both risks and potential benefits. The therapeutic rationale is strongest for people with documented low DHEA-S (age-related decline, adrenal insufficiency, chronic stress).
Drug Interactions
- Aromatase inhibitors: DHEA supplementation may counteract cancer therapeutic aromatase inhibitors
- Testosterone therapy: Combined androgenic effects
- Insulin and diabetes medications: DHEA may affect insulin sensitivity (variable evidence)
- Anticoagulants: Some evidence for DHEA effects on coagulation
Addiction Potential
No addiction potential in the traditional sense, though some individuals may psychologically depend on perceived benefits.
Tolerance
| Full | Not applicable — nutritional supplement |
| Half | N/A |
| Zero | N/A |
Cross-tolerances
Legal Status
This substance is a prescription medication in most major jurisdictions. In the United States, it is not a controlled substance under the Controlled Substances Act but requires a valid prescription from a licensed healthcare provider. It is regulated by the FDA as a pharmaceutical drug.
In the United Kingdom, it is a prescription-only medicine (POM) under the Medicines Act 1968. In the European Union, it is similarly classified as a prescription medicine under EMA regulations. In Australia, it is listed as a Schedule 4 (Prescription Only Medicine) under the Poisons Standard. In Canada, it requires a prescription under the Food and Drugs Act.
Tips (2)
Take DHEA consistently at the same time each day for best results. Many vitamins and nutrients need to build up to steady-state levels before you notice benefits. Give it at least 2-4 weeks.
Quality varies enormously between DHEA supplement brands. Look for products with third-party testing (USP, NSF, ConsumerLab). Cheaper brands may contain fillers, incorrect doses, or contaminants.
See Also
References (3)
- PubChem: DHEA
PubChem compound page for DHEA (CID: 5881)
pubchem - DHEA - TripSit Factsheet
TripSit factsheet for DHEA
tripsit - DHEA - Wikipedia
Wikipedia article on DHEA
wikipedia